t
On 1 July 2025, Celadon Pharmaceuticals Plc confirmed the receipt of £1.0 million in new funds under its Secured Facilities. Following this receipt, the Company intends to proceed with a delisting.
| Date | 1 Jul 2025 |
| Time | 11:48:57 |
| Category | Corporate updates |
| ID | 2360P |
1 July 2025
Celadon Pharmaceuticals Plc
("Celadon" or the "Company")
Funding Update
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines, provides an update on its funding position.
Further to the 30 June 2025 announcement, the Board wishes to confirm receipt of the £1.0 million of new funds under the Secured Facilities. As the funds have now been received, the Company intends to proceed with a delisting and a further announcement on this will be made in due course.
Enquiries:
|
|
|
|
Celadon Pharmaceuticals Plc |
|
|
James Short |
Via Canaccord Genuity Limited |
|
Canaccord Genuity Limited (Nominated Adviser and Broker) |
|
|
Bobbie Hilliam / Andrew Potts
|
+44 (0)20 7523 8000
|
|
|
|
|
Global Investment Strategy UK Limited (Joint Broker) |
+44 (0)20 7048 9400 |
|
James Sheehan |
|
About Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals Plc is a UK-based pharmaceutical company focused on the development, production and sale of breakthrough cannabis-based medicines. Its primary focus is on improving quality of life for chronic pain sufferers, as well as exploring the potential of cannabis-based medicines for other conditions such as autism. Its 100,000 sq. ft UK facility is EU-GMP approved and comprises indoor hydroponic cultivation, proprietary GMP extraction and an analytical and R&D laboratory. Celadon's Home Office licence allows for the commercial supply of its pharmaceutical-grade cannabis product. The Group owns an approved clinical trial using cannabis-based medicinal products to treat chronic pain in the UK. Celadon also has a minority interest in early-stage biopharma Kingdom Therapeutics, which is developing a licensed cannabinoid medicine to treat children with Autism Spectrum Disorder.
For further information please visit our website www.celadonpharma.com
This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.